{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:42:16Z","timestamp":1768542136624,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00115-025-01927-2","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:21:14Z","timestamp":1764598874000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geschlechtsspezifische Aspekte bei der Psychopharmakotherapie","Gender-specific aspects of psychopharmacotherapy"],"prefix":"10.1007","volume":"97","author":[{"given":"Georgios","family":"Schoretsanitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara T.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Paulzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"1927_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/0269881117747578","volume":"32","author":"B Bolea-Alamanac","year":"2018","unstructured":"Bolea-Alamanac\u00a0B, Bailey\u00a0SJ, Lovick\u00a0TA et\u00a0al (2018) Female psychopharmacology matters! Towards a\u00a0sex-specific psychopharmacology. J\u00a0Psychopharmacol 32:125\u2013133","journal-title":"J Psychopharmacol"},{"key":"1927_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/GME.0000000000002292","volume":"31","author":"RP Chikwati","year":"2024","unstructured":"Chikwati\u00a0RP, Chikowore\u00a0T, Mahyoodeen\u00a0NG et\u00a0al (2024) The association of menopause with cardiometabolic disease risk factors in low- and middle-income countries: a\u00a0systematic review and meta-analyses. Menopause 31:77\u201385","journal-title":"Menopause"},{"key":"1927_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1021\/acsptsci.3c00116","volume":"7","author":"M Courchesne","year":"2024","unstructured":"Courchesne\u00a0M, Manrique\u00a0G, Bernier\u00a0L et\u00a0al (2024) Gender Differences in Pharmacokinetics: A\u00a0Perspective on Contrast Agents. ACS Pharmacol Transl Sci 7:8\u201317","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1927_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40263-024-01089-w","volume":"38","author":"M Galbally","year":"2024","unstructured":"Galbally\u00a0M, Wynter\u00a0K, Siskind\u00a0D et\u00a0al (2024) Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia. CNS Drugs 38:559\u2013570","journal-title":"CNS Drugs"},{"key":"1927_CR5","doi-asserted-by":"publisher","unstructured":"Gillessen M, Schmidt CT, Deligiannidis KM et al (2025) The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: A systematic review and meta-analysis. Expert Opin Drug Metab Toxicol 24:1\u201310. https:\/\/doi.org\/10.1080\/17425255.2025.2468197","DOI":"10.1080\/17425255.2025.2468197"},{"key":"1927_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke\u00a0C, Bergemann\u00a0N, Clement\u00a0HW et\u00a0al (2018) Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 51:9\u201362","journal-title":"Pharmacopsychiatry"},{"key":"1927_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41537-023-00430-4","volume":"10","author":"IT Johansen","year":"2024","unstructured":"Johansen\u00a0IT, Steen\u00a0NE, R\u00f8devand\u00a0L et\u00a0al (2024) Sex differences in autonomic adverse effects related to antipsychotic treatment and associated hormone profile. Schizophrenia 10:6","journal-title":"Schizophrenia"},{"key":"1927_CR8","doi-asserted-by":"crossref","unstructured":"Khalil J, Hill H, Kaelber D et\u00a0al (2024) The Association between Hormone Replacement Therapy and Gastroparesis in Post-Menopausal Women: A\u00a0Worldwide Database Analysis. J\u00a0Pers Med 14:","DOI":"10.3390\/jpm14030275"},{"key":"1927_CR9","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/GME.0000000000001579","volume":"27","author":"C Kim","year":"2020","unstructured":"Kim\u00a0C, Saran\u00a0R, Hood\u00a0M et\u00a0al (2020) Changes in kidney function during the menopausal transition: the Study of Women\u2019s Health Across the Nation (SWAN)\u2014Michigan site. Menopause 27:1066\u20131069","journal-title":"Menopause"},{"key":"1927_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/hup.1168","volume":"26","author":"JM Kim","year":"2011","unstructured":"Kim\u00a0JM, Kim\u00a0SW, Stewart\u00a0R et\u00a0al (2011) Predictors of 12-week remission in a\u00a0nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol 26:41\u201350","journal-title":"Hum Psychopharmacol"},{"key":"1927_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1517\/17425255.2011.544250","volume":"7","author":"N Kokras","year":"2011","unstructured":"Kokras\u00a0N, Dalla\u00a0C, Papadopoulou-Daifoti\u00a0Z (2011) Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metab Toxicol 7:213\u2013226","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1927_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41386-018-0156-z","volume":"44","author":"TA Legates","year":"2019","unstructured":"Legates\u00a0TA, Kvarta\u00a0MD, Thompson\u00a0SM (2019) Sex differences in antidepressant efficacy. Neuropsychopharmacology 44:140\u2013154","journal-title":"Neuropsychopharmacology"},{"key":"1927_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/ijnp\/pyac017","volume":"25","author":"C Moderie","year":"2022","unstructured":"Moderie\u00a0C, Nu\u00f1ez\u00a0N, Fielding\u00a0A et\u00a0al (2022) Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression. Int J Neuropsychopharmacol 25:479\u2013488","journal-title":"Int J Neuropsychopharmacol"},{"key":"1927_CR14","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s00115-023-01528-x","volume":"94","author":"M Paulzen","year":"2023","unstructured":"Paulzen\u00a0M, Schoretsanitis\u00a0G (2023) Psychopharmacotherapy during pregnancy and breastfeeding-Part\u00a0I:\u00a0focus on pregnancy : Support options by using therapeutic drug monitoring. Nervenarzt 94:786\u2013798","journal-title":"Nervenarzt"},{"key":"1927_CR15","doi-asserted-by":"publisher","first-page":"111030","DOI":"10.1016\/j.pnpbp.2024.111030","volume":"133","author":"G Schoretsanitis","year":"2024","unstructured":"Schoretsanitis\u00a0G, Deligiannidis\u00a0KM, Kasperk\u00a0N et\u00a0al (2024) The impact of pregnancy on the pharmacokinetics of antiseizure medications: A\u00a0systematic review and meta-analysis of data from 674 pregnancies. Prog Neuropsychopharmacol Biol Psychiatry 133:111030","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1927_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/17425255.2022.2106214","volume":"18","author":"G Schoretsanitis","year":"2022","unstructured":"Schoretsanitis\u00a0G, Deligiannidis\u00a0KM, Paulzen\u00a0M et\u00a0al (2022) Drug-drug interactions between psychotropic medications and oral contraceptives. Expert Opin Drug Metab Toxicol 18:395\u2013411","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1927_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/JCP.0000000000001202","volume":"40","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis\u00a0G, Kane\u00a0JM, De Leon\u00a0J (2020) Adding Oral Contraceptives to Clozapine May Require Halving the Clozapine Dose: A\u00a0New Case and a\u00a0Literature Review. J\u00a0Clin Psychopharmacol 40:308\u2013310","journal-title":"J Clin Psychopharmacol"},{"key":"1927_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1177\/0004867417726584","volume":"51","author":"G Schoretsanitis","year":"2017","unstructured":"Schoretsanitis\u00a0G, Kirner-Veselinovic\u00a0A, Gr\u00fcnder\u00a0G et\u00a0al (2017) Clinically relevant changes in clozapine serum concentrations after breast reduction surgery. Aust N Z J Psychiatry 51:1059\u20131060","journal-title":"Aust N Z J Psychiatry"},{"key":"1927_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/17425255.2020.1750598","volume":"16","author":"G Schoretsanitis","year":"2020","unstructured":"Schoretsanitis\u00a0G, Spigset\u00a0O, Stingl\u00a0JC et\u00a0al (2020) The impact of pregnancy on the pharmacokinetics of antidepressants: a\u00a0systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol 16:431\u2013440","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1927_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin\u00a0OP, Mattison\u00a0DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48:143\u2013157","journal-title":"Clin Pharmacokinet"},{"key":"1927_CR21","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jpsychires.2024.11.014","volume":"181","author":"BWC Storosum","year":"2025","unstructured":"Storosum\u00a0BWC, Cohen\u00a0SE, Mattila\u00a0TK et\u00a0al (2025) Gender differences in the response to antipsychotics or mood stabilizers in patients with acute mania: An individual patient data meta-analysis of placebo-controlled studies. J\u00a0Psychiatr Res 181:358\u2013364","journal-title":"J Psychiatr Res"},{"key":"1927_CR22","doi-asserted-by":"publisher","first-page":"114997","DOI":"10.1016\/j.psychres.2022.114997","volume":"320","author":"BWC Storosum","year":"2023","unstructured":"Storosum\u00a0BWC, Mattila\u00a0T, Wohlfarth\u00a0TD et\u00a0al (2023) Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies. Psychiatry Res 320:114997","journal-title":"Psychiatry Res"},{"key":"1927_CR23","doi-asserted-by":"publisher","first-page":"109299","DOI":"10.1016\/j.steroids.2023.109299","volume":"199","author":"W Thomas","year":"2023","unstructured":"Thomas\u00a0W, Harvey\u00a0BJ (2023) Estrogen-induced signalling and the renal contribution to salt and water homeostasis. Steroids 199:109299","journal-title":"Steroids"},{"key":"1927_CR24","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/aogs.14805","volume":"103","author":"MO Thunbo","year":"2024","unstructured":"Thunbo\u00a0MO, Vendelbo\u00a0JH, Witte\u00a0DR et\u00a0al (2024) Use of medication in pregnancy on the rise: Study on 1.4\u00a0million Danish pregnancies from 1998 to 2018. Acta Obstet Gynecol Scand 103:1210\u20131223","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1927_CR25","first-page":"237","volume":"14","author":"PA Th\u00fcrmann","year":"2007","unstructured":"Th\u00fcrmann\u00a0PA (2007) Arzneimittelanwendung bei Frauen: \u201eOff-Label\u201c? Psychopharmakotherapie 14:237\u2013242","journal-title":"Psychopharmakotherapie"},{"key":"1927_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1055\/s-2006-942089","volume":"82","author":"PA Th\u00fcrmann","year":"2006","unstructured":"Th\u00fcrmann\u00a0PA (2006) Geschlechtsspezifische Aspekte in der Pharmakotherapie \u2013 was ist gesichert? Z\u00a0Allgemeinmed 82:380\u2013384","journal-title":"Z Allgemeinmed"},{"key":"1927_CR27","doi-asserted-by":"publisher","unstructured":"Westin AA, Reimers A, Spigset O (2018) Should pregnant women receive lower or higher medication doses? Tidsskr Nor Laegeforen 138(17). https:\/\/doi.org\/10.4045\/tidsskr.18.0065. Print 2018 Oct 30","DOI":"10.4045\/tidsskr.18.0065"},{"key":"1927_CR28","doi-asserted-by":"publisher","first-page":"e13713","DOI":"10.1111\/cts.13713","volume":"17","author":"JPB Ximenez","year":"2024","unstructured":"Ximenez\u00a0JPB, De Andrade\u00a0JM, Rocha\u00a0A et\u00a0al (2024) Intestinal P\u2011gp activity is reduced in postmenopausal women under breast cancer therapy. Clin Transl Sci 17:e13713","journal-title":"Clin Transl Sci"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01927-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-025-01927-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-025-01927-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T11:45:35Z","timestamp":1768477535000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-025-01927-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1927"],"URL":"https:\/\/doi.org\/10.1007\/s00115-025-01927-2","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Paulzen erhielt in den letzten 2\u00a0Jahren Vortrags- und Beraterhonorare von Neuraxpharm, Lundbeck, Janssen, Johnson&Johnson, Otsuka und Rovi. Er ist Herausgeber von PSIAC, einem internetbasierten Arzneimittelinteraktionsprogramm (\n                      \n                      ). G.\u00a0Schoretsanitis erhielt Vortrags- und Beraterhonorare von Lundbeck, HLS Therapeutics und Saladax. G.\u00a0Schoretsanitis, C.T.\u00a0Schmidt und M.\u00a0Paulzen gaben an, dass bez\u00fcglich der Erstellung des Beitrags keine Interessenkonflikte bestanden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}